Your selection
Innovation / 13.08.2026
Eckert & Ziegler Remains on Track in the First Half of 2026
2nd Quarter 2026:
- Sales: €76.4 million (PY: €80.6million)
- EBIT before special items: €17.4 million (PY: €19.2 million)
- Net income: €12.1 million (PY: €11.8 million)
1st Half Year 2026:
- Sales: €149.3 million (PY: €148.8 million)
- EBIT before special items: €33.3 million (PY: €35.4 million)
- Net income: €22.4 million (PY: €21.4 million)
Forecast 2026:
- Sales of around €320 million (confirmed)
- EBIT before special items of around €80 million (confirmed)
Berlin, 13 August 2026. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) reported sales of €149.3 million in the first half of 2026. The group’s adjusted EBIT dropped by just under 6% to €33.3 million. Adjusted EBIT in the Medical segment rose by nearly 7% to €24.9 million. Net income grew by approximately 5% to €22.4 million, or €0.36 per share. Adjusted for the extraordinary licensing revenue in the same period of the previous year, group sales increased by 4% and earnings by as much as 9%. The licensing business had not yet generated revenues in 2026.
In the Medical segment, sales in the first half of the year totaled €80.9 million, slightly above the prior-year level (€80.5 million). The pharmaceutical radioisotopes business remains the most important revenue driver. The Isotope Products segment generated sales of €68.5 million, which were nearly unchanged compared with the prior year.
For the current fiscal year 2026, the Executive Board confirms its profit forecast published on
26 March 2026, with sales of around €320 million and an adjusted EBIT of around €80 million.
The complete quarterly report can be viewed here: https://www.ezag.com/Q22026en
About Eckert & Ziegler.
Eckert & Ziegler SE with more than 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.
Overview News
News Buch Berlin
Eckert & Ziegler Remains on Track in the First Half of 2026
Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) reported sales of €149.3 million in the first half of 2026. The group’s adjusted EBIT dropped by just under 6% to €33.3 million. Adjusted EBIT in the Me...
more ...The path of new immunotherapies to the clinic
Bringing a new CAR‑T cell therapy from promising results in the lab to critically ill cancer patients is anything but straightforward. A Tagesspiegel podcast featuring, among others, Armin Rehm explor...
more ...OMEICOS’ OMT-28 Headed for Phase 3 in Primary Mitochondrial Diseases (PMD) Following Positive End-of-Phase 2 Meeting with the FDA
OMEICOS, a late-stage clinical biopharmaceutical company developing first-in-class small-molecule therapeutics for mitochondrial and inflammatory disorders, today announced the successful completion o...
more ...Events Buch Berlin
25.08.2026, 18:00
Campus-Kino: "Choices of the heart - the Margaret Sanger Story"
Film über die Krankenschwester Margaret Sanger, die 1914 zur wegweisenden Kämpferin für die Rechte von Frauen wurde.
more ...25.08.2026, 18:30
Podiumsdiskussion mit Politiker:innen zum Schwerpunkt Wohnungsbauvorhaben in Buch, speziell "Buch am Sandhaus"
Unter anderem geht es um den Schutz der angrenzenden Naturräume, die Moorwiese, den Ausbau des ÖPNV und Anpassungen des B-Plans 3 - 95
more ...01.09.2026, 08:00
Aktualisierungskurs für Projektleiter und Beauftragte für Biologische Sicherheit nach § 28 GenTSV
Ein-Tages-Onlinekurs mit gesetzlich vorgeschriebenen Lehrinhalten, anerkannt und zertifiziert vom Landesamt für Gesundheit und Soziales (LAGeSo)
more ...